$CALC

CalciMedica (CALC) details 2025 executive pay, ownership and $20.4M raise

CalciMedica (CALC) has filed an amendment to its annual report (10-K/A), detailing 2025 executive compensation, board governance, ownership stakes, and related-party transactions, as well as a $20.4 million private placement from 2024. The filing specifies executive pay, significant equity awards, and severance policies, with CEO A. Rachel Leheny receiving $895,410 in total compensation for 2025. It also updates information on major shareholders and outlines fees paid to the independent auditor.

Original reporting
Published May 1, 2026, 7:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 1, 2026, 8:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CALC
Neutral
medium confidence
Mentioned
$CALC · $CALC
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$CALCNeutralLow
01

Why it matters

The disclosures improve transparency, which could bolster investor confidence, but lack immediate catalysts for stock movement.

02

Market read

The news is relevant for investors interested in CALC's fundamentals and governance, with limited immediate trading impact.

03

What to watch

Potential upcoming regulatory changes or market conditions affecting biotech funding and valuations that are not addressed in this news.

Timing: long-term

Background

CalciMedica is a biotech company with recent activities including a significant private placement and detailed governance disclosures, indicating ongoing development and funding.

Company-level read

Ticker impact

$CALCNeutralMedium confidence
Context

The news pertains directly to CalciMedica's financial disclosures, executive compensation, ownership, and recent funding activities, which are highly relevant for current and potential investors.

Expected impact

Limited immediate impact; potential for long-term growth if funding translates into operational success.

Evidence & confidence

While the financial details are comprehensive, they do not signal immediate market-moving events. The neutral sentiment and lack of significant positive or negative cues suggest limited short-term price volatility.

$CALCNeutralMedium confidence
Context

The news provides detailed insights into CALC's financial and governance activities, which are relevant for investors monitoring company fundamentals.

Expected impact

Potential for minor positive movement over the medium term as transparency improves investor perception.

Evidence & confidence

The news enhances transparency but lacks immediate catalysts for significant price changes. The impact depends on how investors interpret the company's governance and funding activities.

Market effects

The updates on corporate governance and funding may positively influence investor confidence in biotech and life sciences sectors.

Limited regional impact; specific to CALC and its immediate investor base.

Minimal; company-specific news with limited global market implications.

Counterpoint

Some investors may interpret the detailed disclosures as a sign of underlying issues or strategic shifts that could negatively impact stock performance.

Key entities

  • A. Rachel Leheny

    CEO of CalciMedica, received $895,410 in total compensation for 2025.

  • CalciMedica

    Biotech firm with recent financial disclosures and funding activities.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.